AMAG Pharmaceuticals (AMAG) announced a study of its drug Feraheme (ferumoxytol) that makes it an acquisition candidate. New study from a head-to-head trial comparing Feraheme Injection for intravenous use to iron sucrose in patients with iron deficiency anemia and chronic kidney disease is positive for AMAG Pharmaceuticals. The data was presented in the late-breaking clinical trials poster session at the American Society of Nephrology.
If and when six screens of the ZYX Change Method are satisfied, we will issue a buy signal on the Real Time Feed of the ZYX Buy Change Alert.
